DAX23.999 -0,5%ESt505.424 -0,6%Top 10 Crypto15,33 +3,3%Dow42.021 +0,4%Nas19.020 +0,8%Bitcoin98.896 +2,2%Euro1,1269 -0,5%Öl64,23 -0,5%Gold3.298 -0,5%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
Rheinmetall 703000 RENK RENK73 NVIDIA 918422 D-Wave Quantum A3DSV9 Siemens Energy ENER6Y BYD A0M4W9 Tesla A1CX3T HENSOLDT HAG000 freenet A0Z2ZZ Deutsche Bank 514000 Bayer BAY001 Deutsche Telekom 555750 Infineon 623100 Lufthansa 823212 Allianz 840400
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
DAX schließt unterhalb der 24.000er-Marke -- Umsatz von Snowflake knackt die Milliarde -- Bitcoin mit neuem Rekord -- Beiersdorf, Metaplanet, Strategy, Innoscripta, Rheinmetall im Fokus
Top News
Webinar: Investieren im Zollschock - Chancen, Risiken, Strategien Webinar: Investieren im Zollschock - Chancen, Risiken, Strategien
Salzgitter und Papenburg setzen Partnerschaft fort - Salzgitter-Aktie verliert Salzgitter und Papenburg setzen Partnerschaft fort - Salzgitter-Aktie verliert
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil

REGENXBIO Aktie

NeuKaufenVerkaufen
REGENXBIO Aktien-Sparplan
8,40 EUR -0,30 EUR -3,45 %
FSE
10,09 USD +0,45 USD +4,67 %
BTT
Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!
JETZT LOSLEGEN
Du hast schon ein ZERO-Konto? Direkt handeln bei ZERO!Bei einem anderen Broker handelnSmartphone

Marktkap.428,75 Mio. EUR

Div. Rendite0,00%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKNA140E0

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINUS75901B1070

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolRGNX

REGENXBIO Aktien News

DatumMeistgelesen
PR NewswireREGENXBIO to Participate in Chardan's 8th Annual Genetic Medicines Conference
PR NewswireREGENXBIO Appoints Mitchell Chan as Chief Financial Officer
BenzingaAssessing Regenxbio: Insights From 5 Financial Analysts
PR NewswireREGENXBIO Announces Positive Data from Pivotal Dose Level of RGX-121 Demonstrating Long-Term Systemic Effect
PR NewswireREGENXBIO to Participate in Upcoming Investor Conferences
PR NewswireREGENXBIO Announces Presentation at the Society for the Study of Inborn Errors of Metabolism (SSIEM) 2024 Annual Symposium
PR NewswireREGENXBIO to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference
ZacksWall Street Analysts Think Regenxbio (RGNX) Could Surge 234.37%: Read This Before Placing a Bet
BenzingaWhere Regenxbio Stands With Analysts
ZacksRegenxbio (RGNX) Reports Q2 Loss, Tops Revenue Estimates
PR NewswireREGENXBIO Reports Second Quarter 2024 Financial Results and Recent Operational Highlights
PR NewswireREGENXBIO ANNOUNCES NEW POSITIVE DATA FROM AFFINITY DUCHENNE® TRIAL OF RGX-202
PR NewswireREGENXBIO to Host Conference Call on August 1 to Discuss Second Quarter 2024 Financial Results and Recent Operational Highlights
ZacksRegenxbio (RGNX) Surges 18.3%: Is This an Indication of Further Gains?
ZacksRegenxbio (RGNX) Soars 6.4%: Is Further Upside Left in the Stock?
PR NewswireREGENXBIO Announces Expansion of AFFINITY DUCHENNE® Trial to Include a New Cohort of Younger Patients
PR NewswireREGENXBIO Announces Successful Pre-BLA Meeting with FDA to Support Accelerated Approval Pathway for RGX-121 for the Treatment of MPS II
PR NewswireREGENXBIO Announces Leadership Transition
BenzingaAssessing Regenxbio: Insights From 4 Financial Analysts
PR NewswireREGENXBIO to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
PR NewswireREGENXBIO to Participate in Upcoming Investor Conferences
PR NewswireREGENXBIO Reports First Quarter 2024 Financial Results and Recent Operational Highlights
PR NewswireREGENXBIO to Host Conference Call on May 8 to Discuss First Quarter 2024 Financial Results and Recent Operational Highlights
PR NewswireREGENXBIO to Participate in Chardan's 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit
PR NewswireREGENXBIO Announces Lancet Publication of Phase I/IIa Study Evaluating ABBV-RGX-314 as a One-Time Gene Therapy for Wet AMD
PR NewswireREGENXBIO to Participate in Cantor Fitzgerald's Virtual DMD and Other Dystrophy Days
PR NewswireREGENXBIO to Participate in Upcoming Investor Conferences
PR NewswireREGENXBIO ANNOUNCES NEW POSITIVE INITIAL EFFICACY DATA FROM AFFINITY DUCHENNE® TRIAL
PR NewswireREGENXBIO to Host Webcast Event to Discuss New Interim Clinical Data from the Phase I/II AFFINITY DUCHENNE® Trial
PR NewswireREGENXBIO Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Highlights
PR NewswireREGENXBIO to Host Conference Call on February 27 to Discuss Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Highlights
PR NewswireREGENXBIO Announces Pivotal Trial of RGX-121 for the Treatment of MPS II Achieves Primary Endpoint
PR NewswireREGENXBIO Announces Completion of Enrollment in Cohort 2 and Additional Positive Interim Data in AFFINITY DUCHENNE® Trial
PR NewswireREGENXBIO Announces Presentations at the 20th Annual WORLDSymposium 2024
PR NewswireREGENXBIO Announces Positive Interim Data from Phase II AAVIATE® Trial of ABBV-RGX-314 for the Treatment of Wet AMD Using Suprachoroidal Delivery
PR NewswireREGENXBIO Announces Presentation at the Hawaiian Eye and Retina 2024 Meeting
PR NewswireREGENXBIO Announces Dose Escalation in AFFINITY DUCHENNE® Trial
PR NewswireREGENXBIO Announces Updated Strategic Plans and Third Quarter 2023 Financial Results
PR NewswireREGENXBIO to Participate in Upcoming Investor Conferences
PR NewswireREGENXBIO Presents Positive One Year Data from Phase II ALTITUDE® Trial of ABBV-RGX-314 for Treatment of Diabetic Retinopathy Using Suprachoroidal Delivery
Wer­bung

REGENXBIO News

REGENXBIO News: auf dieser Seite finden Sie alle REGENXBIO News und Nachrichten zur REGENXBIO Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch REGENXBIO News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um REGENXBIO News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.